Aligos Therapeutics, Inc. has entered into a Securities Purchase Agreement to sell approximately 2.1 million shares of common stock and warrants, raising about $105 million in gross proceeds. The closing is expected on February 13, 2025, with various conditions and rights agreements established for the investors.